AGIO Agios Pharmaceuticals Inc

NASDAQ
$28.76

Agios Pharmaceuticals Inc (AGIO) Earnings News

Earnings press releases, previews and reviews for Agios Pharmaceuticals Inc (AGIO), newest first. Our most recent is review: Agios Beats on Record Mitapivat Sales, but a Sickle Cell Delay and Slowing Script Adds Complicate the Story.

Thursday November 5, 2026 9:47 AM ET
Agios Beats on Record Mitapivat Sales, but a Sickle Cell Delay and Slowing Script Adds Complicate the Story
Earnings Whispers · Review
Thursday November 5, 2026 6:30 AM ET
Agios Reports Third Quarter 2026 Financial Results and Provides Business Update
Wednesday November 4, 2026 9:01 AM ET
Agios to Highlight Strength and Differentiation of Rare Hematology Portfolio with New Clinical Data for Mitapivat in Sickle Cell Disease and AG-236 in Polycythemia Vera at ASH 2026
Friday October 30, 2026 7:00 AM ET
Agios Announces New PDUFA Goal Date of February 1, 2027, for Mitapivat Sickle Cell Disease sNDA; Company Is Launch-Ready and in Labeling Discussions with FDA
Wednesday October 28, 2026 1:04 PM ET
Agios Faces First Clean Test of Akvesme Launch Days After Sickle Cell Decision
Earnings Whispers · Preview
Tuesday October 20, 2026 8:59 AM ET
A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday
Thursday October 8, 2026 7:00 AM ET
Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ET
Thursday July 30, 2026 6:30 AM ET
Agios Reports Second Quarter 2026 Financial Results and Provides Business Update
Tuesday July 21, 2026 7:00 AM ET
Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease
Tuesday July 7, 2026 7:00 AM ET
U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease
Monday June 29, 2026 7:00 AM ET
Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 a.m. ET
Saturday June 13, 2026 9:00 AM ET
Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease
Monday June 1, 2026 5:00 AM ET
Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib
Friday May 29, 2026 7:00 AM ET
Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes
Friday May 22, 2026 9:15 AM ET
Agios’ PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia